Castle Biosciences (CSTL) Assets (2018 - 2026)

Castle Biosciences has disclosed Assets across 9 years of filings, most recently posting $561.2 million for Q2 2026.

• In Q2 2026, Assets rose 3.02% year-over-year to $561.2 million; the TTM figure through Jun 2026 stood at $561.2 million (up 3.02% YoY), while the FY2025 annual figure was $578.6 million, up 8.91% from the prior year.
• Assets came in at $561.2 million for Q2 2026 at Castle Biosciences, up from $547.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $578.6 million in Q4 2025 to a low of $425.4 million in Q2 2023.
• Average Assets over 5 years is $491.0 million, with a median of $472.9 million recorded in 2024.
• Year-over-year, Assets decreased 7.19% in 2023 and gained 18.01% in 2024.
• Over 5 years, Assets stood at $447.3 million in 2022, then gained by 1.34% to $453.3 million in 2023, then climbed by 17.18% to $531.2 million in 2024, then rose by 8.91% to $578.6 million in 2025, then slipped by 3.0% to $561.2 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $561.2 million in Q2 2026, $547.8 million in Q1 2026, and $578.6 million in Q4 2025.